Ipca Laboratories Limited

NSE IPCALAB.NS

Ipca Laboratories Limited Debt to Equity Ratio for the year ending March 31, 2024: 0.23

Ipca Laboratories Limited Debt to Equity Ratio is 0.23 for the year ending March 31, 2024, a -10.41% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Ipca Laboratories Limited Debt to Equity Ratio for the year ending March 31, 2023 was 0.25, a 72.50% change year over year.
Ipca Laboratories Limited Debt to Equity Ratio for the year ending March 31, 2022 was 0.15, a 160.40% change year over year.
Ipca Laboratories Limited Debt to Equity Ratio for the year ending March 31, 2021 was 0.06, a -59.11% change year over year.
Ipca Laboratories Limited Debt to Equity Ratio for the year ending March 31, 2020 was 0.14, a -7.30% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NSE: IPCALAB.NS

Ipca Laboratories Limited

CEO	Mr. Pranay Premchand Godha
IPO Date	Jan. 1, 1996
Location	India
Headquarters	125, Kandivli Industrial Estate
Employees	17,335
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Key trends

Past 5 years